Oral Hormone Pregnancy Tests

Debate between Yvonne Fovargue and Yasmin Qureshi

Thursday 23rd October 2014 Commons Chamber

[Yvonne Fovargue (Makerfield) (Lab)]

My constituent, the wonderful campaigner Marie Lyon, has doggedly pursued this issue, and I think we can fairly say that that has led to my hon. Friend getting this excellent debate. I am aware of two constituents who have been affected by this drug. Mr and Mrs Tilley’s son Stephen was born with brain damage, and when they asked for Mrs Tilley’s medical records, they found they were missing. This is not the first case I have heard about of records being lost or destroyed in this regard. Is my hon. Friend as concerned as I am about this apparent cover-up?

[Yasmin Qureshi]

I entirely agree with my hon. Friend about the cover-up.

We have recently discovered another document in the Kew archive: a letter from the 1960s about the minutes of a meeting of the General Medical Services Committee, in which Dr Inman was involved. It says that there was worry about a request by the Committee on Safety of Medicines that doctors should be monitoring adverse reactions to medication. Doctors were a bit concerned about that in case they might be liable for negligence actions. The minutes say that doctors should stop recording adverse reactions, and, even more significantly, that those who have recorded any such evidence should have it destroyed. That fits in with the constituents, including mine, who have said that when they, as parents, have gone to their doctors to get their records, they are somehow mysteriously missing.

A British medical director of British-based Schering Chemicals, which is a subsidiary of Bayer Schering in Berlin, urged the withdrawal of the hormone pregnancy drug primodos in 1969, but his plea was rejected by the company. In the same year, the author of a survey for the Royal College of General Practitioners also recommended the withdrawal of the drug, but he, too, was turned down. Until this day, Bayer has refused to take any responsibility.

Jason Farrell, the Sky News reporter I mentioned, has met the statistician, Dennis Cooke, who was contracted by Schering in the ’60s. In a report, of which he still has copies, he compared the increase in the sales of primodos with the number of recorded deformities in newborns, which, he says,

“show a rather alarming direct and strong correlation.”

Schering stopped promoting primodos in 1970, and prescriptions fell from 120,000 in that year to 7,000 by 1977, when it was withdrawn. National statistics show that birth deformities declined during that period as well.

Another person I want to allude to is Professor Briggs. Many times, whenever it has been contacted about this, Bayer has referred to the court case of 1982. It is important to explain to the House that the damage claims brought by the victims were discontinued in the 1980s because some of the medical witnesses defected to the defendants, Schering Chemicals, so the case had to be withdrawn. Some of the victims say that the so-called experts who went over to the Schering side had an interesting story. One of those was Professor Briggs. Some years after the case collapsed, The Sunday Times published an interview with Professor Briggs by Brian Deer, a journalist, in which he accepts that he had in the past “fabricated” studies and carried out

“scientific fraud on a large scale”.

That is on the internet and can be read by anyone.

On a CD that has been kept under lock and key—there is an injunction on it—Professor Briggs is heard confessing:

“Difficulties would be encountered if doubts expressed about hormone pregnancy tests were made public. These were exactly the same hormones as the contraceptive pill and would have cast doubt on the safety of hormones which would extend doubt on the safety of the Pill. This would have a major influence on worldwide family planning which could be a real human disaster. It could cause panic among millions of women worldwide which could result in thousands of pregnancies.”

Later he claims:

“Drugs such as these would never be allowed to be on the Market today, given what we ‘now know’ and following what we know about Potential Hazards to the developing Foetus.”

Those comments were made in a documentary called “The Primodos Affair”, which has never been aired because Schering took out an injunction. Why did it do that? What did it have to hide?

There is further curious evidence regarding other witnesses. Dr Smithills approached a drug company for which he was doing research work on the drug Debendox. He suggested that he would approve the drug and that a funded research project would be an appropriate reward. Dr Inman opened a research centre soon after the case, after he left the Committee on Safety of Medicines. And guess what? Professor Briggs also opened a research centre in Australia soon after the case.

I have no hesitation in saying that those witnesses were bought off by Schering. It is amazing how all of them ended up opening research centres, which, as everybody knows, costs money.

Obviously, the situation is not this Government’s fault, but no Government have taken action over the years. Given the weight of evidence, why did the regulators not warn the doctors? According to internal correspondence from the Committee on Safety of Medicines, it admits that it has

“no defence for the 8 year delay”.

Interestingly, the authorities in Sweden, Finland, Germany, the USA, Australia, Ireland and Holland issued warnings and took action on the drug as early as 1970, five years before any warning was issued in the UK, despite the fact that the first group that knew about the problem was the Committee on Safety of Medicines.

One of the things thrown at the victims is the claim that there is no link, but there is a link: so many statistics show a correlation and so many doctors saw what happened. There seems to have been a complete failure on the part of the body appointed to monitor medication. It could have taken action but failed to do so, so the Government of the day were culpable.

Interestingly, Schering discontinued the product and stopped using it for pregnancy tests. Surely that suggests that something was wrong with the drug; otherwise, it would not have been taken off the market.

It is said that justice delayed is justice denied. We have found out in recent years about cover-ups in relation to so many tragedies, including thalidomide, Hillsborough and the sexual abuse of children in care homes and institutions. The 1960s and ’70s seem to have been an era of cover-ups, wherever we look, and victims in those cases campaigned for years and years to get an inquiry. The case under discussion has been going on for 30 to 40 years. Is it not about time for the victims—there are thousands of them—to get the justice they deserve?

NHS Reorganisation

Debate between Yvonne Fovargue and Yasmin Qureshi

Wednesday 17th November 2010 Commons Chamber

[Yvonne Fovargue (Makerfield) (Lab)]

Does my hon. Friend agree that the description of a consortium of GPs—a loose affinity of people with whom they get on rather than a geographical boundary—and the loss of co-terminosity will affect patients? Indeed, it will not simply be a postcode lottery, but, across the board, a matter of whom a patient is registered with.

[Yasmin Qureshi]

I thank my hon. Friend for that intervention. Some years ago, when that sort of process was introduced in the legal system, with solicitors able to apply for franchises, the big firms benefited and the smaller, local firms went bust. A similar thing will happen. Some GPs, who run small surgeries in the heart of a community, will not be able to form consortiums. What happens to them? Does it mean that people in parts of Kearsley in my constituency will have to travel seven miles to go to a big GP consortium rather than being able to walk down the street and speak to their GPs, as they currently do?

The reform means that private patients will have a chance to pay for faster care in the NHS. Now that the restriction on the income that can be made from private patients is being lifted, cash-strapped hospitals will find it difficult to resist that income stream. Patients could routinely be offered that route to faster treatment. Thus wealthier people can queue jump, while NHS patients will linger on a lengthening waiting list.

I know that the Secretary of State—